Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 7, 2016, Pages 1853-1858

  Nakaya, Helder I ^a,b   Clutterbuck, Elizabeth ^c   Kazmin, Dmitri ^d   Wang, Lili ^c   Cortese, Mario ^d   Bosinger, Steven E ^d   Patel, Nirav B ^d   Zak, Daniel E ^e   Aderem, Alan ^e   Dong, Tao ^c   Del Giudice, Giuseppe ^f   Rappuoli, Rino ^f   Cerundolo, Vincenzo ^c   Pollard, Andrew J ^c   Pulendran, Bali ^b,d   Siegrist, Claire Anne ^g  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d EMORY UNIVERSITY   (United States)

^e SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^g UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Adjuvant; Children; Influenza vaccine; MF59; Systems biology

Indexed keywords

CD4 ANTIGEN; INFLUENZA VACCINE; MIFAMURTIDE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; TRANSCRIPTOME; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MEMORY CELL; PHASE 2 CLINICAL TRIAL; PLASMABLAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SYSTEMS BIOLOGY; VACCINATION; B LYMPHOCYTE; BIOSYNTHESIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFANT;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; INFLUENZA VACCINES; POLYSORBATES; SQUALENE; SYSTEMS BIOLOGY; TRANSCRIPTOME;

EID: 84994525492     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1519690113     Document Type: Article

References (25)

1. Wong KK, et al. (2013) Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics 132(5): 796-804.
2. Vesikari T, et al. (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365(15): 1406-1416.
3. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V (2008) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev (2): CD004879.
4. Ritzwoller DP, et al. (2005) Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 116(1): 153-159.
5. Esposito S, et al. (2011) Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 127(5): e1161-e1168.
6. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M (2009) MF59-adjuvanted influenza vaccine (FLUAD) in children: Safety and immunogenicity following a second year seasonal vaccination. Vaccine 27(45): 6291-6295.
7. Zedda L, et al. (2015) Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. Pediatr Infect Dis J 34(1): 73-78.
8. Calabro S, et al. (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29(9): 1812-1823.
9. Galli G, et al. (2009) Adjuvanted H5N1 vaccine induces early CD4+Tcell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106(10): 3877-3882.
10. Khurana S, et al. (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3(85): 85ra48.
11. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD (2013) The history of MF59(®) adjuvant: A phoenix that arose from the ashes. Expert Rev Vaccines 12(1): 13-30.
12. Pulendran B, Li S, Nakaya HI (2010) Systems vaccinology. Immunity 33(4): 516-529.
13. Li S, et al. (2014) Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15(2): 195-204.
14. Querec TD, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10(1): 116-125.
15. Nakaya HI, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12(8): 786-795.
16. Furman D, et al. (2013) Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 9: 659.
17. Cao RG, et al. (2014) Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. J Infect Dis 210(2): 224-233.
18. Black S, et al. (2011) Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30(12): 1081-1085.
19. Wrammert J, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195): 667-671.
20. Tan Y, et al. (2014) Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. Eur J Immunol 44(1): 285-295.
21. Franco LM, et al. (2013) Integrative genomic analysis of the human immune response to influenza vaccination. eLife 2: e00299.
22. Kwissa M, Nakaya HI, Oluoch H, Pulendran B (2012) Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119(9): 2044-2055.
23. Kauffmann A, Gentleman R, Huber W (2009) arrayQualityMetrics - A bioconductor package for quality assessment of microarray data. Bioinformatics 25(3): 415-416.
24. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP (2007) GSEA-P: A desktop application for Gene Set Enrichment Analysis. Bioinformatics 23(23): 3251-3253.
25. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43): 15545-15550.